Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib and Ventoclax: A Phase II Study
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2019
Price : $35 *
At a glance
- Drugs Dasatinib (Primary) ; Venetoclax (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 09 May 2019 Planned End Date changed from 1 Feb 2019 to 31 Dec 2040.
- 09 May 2019 Planned primary completion date changed from 1 Feb 2019 to 31 Dec 2040.